TrialVaccine2022

Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial.

Kriangkrai Tawinprai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.